Lower GI Series Market - Growth Drivers - Eisai , Cadila Pharmaceuticals, PeaceHealth, Purdue Pharma L.P., Alfa Wassermann, NOVADAQ, Mount Sinai Beth Israel, AstraZeneca, and Ironwood Pharmaceuticals Inc. | Strategic Analysis 2023

The report gives detail analysis of the market structure along with forecast, market size & share, different segments and developing trends of the industry.

Global Lower Gi Series Market - Overview

Gastrointestinal diseases has gained a tremendous attention over the last few years. Increasing prevalence of different gastrointestinal diseases and disorders has encouraged many companies for initiating the research & development for innovative and advanced drugs, diagnostics, and therapeutic approaches.

Get Sample Copy for Future Advancements @ https://www.marketresearchfuture.com/sample_request/771

A Lower Gastrointestinal (GI) Series or Barium Enema test provides a series of X-ray images of the large intestine. A lower Gi series is most commonly used to screen for colorectal cancer and bowel diseases.

It is helpful for determining the cause of bleeding, pain, bowel obstruction, or changes in bowel movements. Upon modification of this test to a Double-Contrast Barium Enema, and with the use of fluoroscope, it can be used to view inside the large intestine to provide a better view of the mucous membrane.

Global Lower Gi Series Market – Growth and Analysis

According to a recent study report published by the Market Research Future analysts, the global lower Gi series market is currently very steady and growing at a moderate rate.

This market is mainly driven by the factors such as increasing prevalence of GI diseases, rising geriatric population and increasing investment in research & development. Additionally, changing lifestyle and increasing awareness about the availability of the treatment fuel the market growth.

Having said that, development of an alternative diagnostic tests, and increasing use of colonoscopies may hinder the growth of the lower GI series market to an extent.

Global Lower Gi Series Market - Competitive Analysis

The global lower Gi series market consists of number of healthcare providers and tests available in the market. The market demonstrates steady growth. Further resulting in intensified competition.

Top players are investing heavily in R&D and clinical trials to develop effective procedures for diagnostics in the GI space. There are few developments in the market with respect to lower GI series.

Ironwood Pharmaceuticals, Inc. is a manufacturer of different types of medicines. One of the drugs manufactured by this company is Linaclotide which is approved by the U.S. Food and Drug Administration and marketed since December 2012.

Read Comprehensive Overview of Report @ https://www.marketresearchfuture.com/reports/lower-gi-series-market-771

Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan, It has launched number of products used as contrast media.

The global market consist of players such as Eisai Co. Ltd. (Japan), Cadila Pharmaceuticals Limited (India), PeaceHealth (U.S.), Purdue Pharma L.P. (U.S.), Alfasigma SpA (Italy), Mount Sinai Beth (Israel), South Sound Radiology (U.S.), AstraZeneca (U.K.) and Ironwood Pharmaceuticals (U.S.)

Global Lower GI series Market - Regional Analysis

The global lower GI series market is growing at a moderate rate. This market is greatly benefitted by the increased aging population in the major regions all across the world. America region captured a significant share of the global lower GI series market.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, more than 34 million Americans have GI tract diseases out of which 20 million American have chronic diseases.

Such huge population in United States which are more prone to the gastrointestinal diseases such as Ulcerative colitis, colon cancer, Crohn’s disease, and others have majorly driving the growth of the lower Gi series market in this region.

European market is second highest revenue generator after America. Europe lower Gi series market has benefited by the presence of some major healthcare providers, and diagnostic laboratories in this region.

Asia Pacific region is the fastest growing region in lower GI market owing to the rising population with the gastrointestinal problems.

For Exclusive Discount Visit @ https://www.marketresearchfuture.com/check-discount/771

Major Points form TOC for Lower GI Series Market Research Report – Forecast to 2023

Chapter 1. Report Prologue

Chapter 2. Market Introduction

Chapter 3. Research Methodology

Chapter 4. Market Dynamics

Chapter 5. Market Factor Analysis

Chapter 6. Global Lower GI Series Market, By Type

Chapter 7. Global Lower GI Series Market, By Treatment

Chapter 8 Global Lower GI Series Market, By End User

Chapter 9. Global Lower GI Series Market, By Region

Chapter 10. Company Landscape

Chapter 11. Company Profiles

Chapter 12. MRFR Conclusion

Chapter 13. Appendix

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.